SEC Form 4 · accession 0000899243-18-018334

· DNTH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 25, 2018

Accepted (ET)

Jun 27, 2018 · 4:31 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001690585

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jun 25, 2018	C	593,611	—	A	593,611	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series B Preferred Stock^F1,F2	—	Jun 25, 2018	C	1,287,100	D	—	—	Common Stock	498,107	0	I
Series C Preferred Stock^F1,F2	—	Jun 25, 2018	C	246,781	D	—	—	Common Stock	95,504	0	I

F1The Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.
F2The shares are held directly by Be The Match BioTherapies, LLC ("Be the Match"). Ms. Ronneberg is President of Be The Match and disclaims beneficial ownership of such securities, except to the extent of her pecuniary interest therein, if any.